Lipoprotein lipase expression, serum lipid and tissue lipid deposition in orally-administered glycyrrhizic acid-treated rats

Lipids in Health and Disease

Volumn 8, Issue , 2009, Pages

  Lim, Wai Yen Alfred ^a   Chia, Yoke Yin ^a   Liong, Shih Yeen ^a   Ha Ton, So ^a   Kadir, Khalid Abdul ^a   Syed Husain, Sharifah Noor Akmal ^b  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLYCYRRHIZIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; 11BETA HYDROXYSTEROID DEHYDROGENASE; ENZYME INHIBITOR;

ABDOMINAL WALL MUSCULATURE; ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DRUG ACTIVITY; FATTY ACID BLOOD LEVEL; HEART; INTRAABDOMINAL FAT; KIDNEY PARENCHYMA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; RAT; SUBCUTANEOUS TISSUE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; BLOOD PRESSURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; KIDNEY; METABOLIC SYNDROME X; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT; WHITE ADIPOSE TISSUE;

GLYCYRRHIZA; GLYCYRRHIZA GLABRA; RATTUS;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADIPOSE TISSUE, WHITE; ANIMALS; BLOOD PRESSURE; CELL SIZE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCYRRHIZIC ACID; KIDNEY; LIPID METABOLISM; LIPIDS; LIPOPROTEIN LIPASE; LIVER; METABOLIC SYNDROME X; MUSCLE, SKELETAL; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC;

EID: 69249149277     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-8-31     Document Type: Article

References (44)

1. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. K Preiss-Landi R Zimmermann G Hammerle R Zechner, Curr Opin Lipidol 2002 13 5 471 481 12352010
2. Lipoprotein lipase as a therapeutic target for dyslipidemia. S Pillarisetti U Saxena, Front Biosci 2003 8 d238 241 12456348
3. A review of the metabolic syndrome. B Balkau P Valensi E Eschwege G Slama, Diabetes Metab 2007 33 405 413 17981485
4. The metabolic syndrome. T Fulop D Tessier A Carpentier, Pathologie Biologie 2006 54 375 386 16904849
5. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. G Boden GI Shulman, Eur J Clin Invest 2002 32 3 14 23 12028371
6. Lipids and Lipoproteins in Patients With Type 2 Diabetes. R Krauss, Diabetes Care 2004 27 6 1496 1504 15161808
7. Pathophysiology of dyslipidaemia in the metabolic syndrome. GD Kolovou KK Anagnostopoulou DV Cokkinos, Postgrad Med J 2005 81 358 366 15937200
8. Insulin Resistance as the Underlying Cause for the Metabolic Syndrome. D Lann D LeRoith, Med Clin N Am 2007 91 1063 1077 17964909
9. Lipoprotein lipase: structure, function, regulation and role in disease. JR Mead SA Irvine DP Ramji, J Mol Med 2002 80 753 769 12483461
10. Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. H Kageyama T Hirano K Okada T Ebara A Kageyama T Murakami S Shioda M Adachi, Biochem Biophys Res Commun 2003 305 22 27 12732191
11. Alterations in plasma and tissue lipids associated with obesity and the metabolic syndrome. CM Aguilera M Gil-Campos R Canete A Gil, Clin Sci 2008 114 183 193 18184112
12. Intramuscular Lipid Content Is Increased in Obesity and Decreased by Weight Loss. BH Goodpaster R Theriault SC Watkins DE Kelley, Metabolism 2000 49 4 467 472 10778870
13. The life cycle of neutral lipids: synthesis, storage and degradation. K Athenstaedt G Daum, Cellular and Molecular Life Sciences 2006 63 1355 1369
14. Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity and Glucose Tolerance in 11beta-Hydroxysteroid Dehydrogenase Type 1 Null Mice. MM Morton MC Holmes C Fievet B Staels A Tailleux JJ Mullins JR Seckl, J Biol Chem 2001 276 44 41293 41300 11546766
15. Is 11beta-Hydroxysteroid Dehydrogenase Type 1 a Therapeutic Target? Effects of Carbenoxolone in Lean and Obese Zucker Rats. DEW Livingstone BR Walker, J Pharmacol Exp Ther 2003 305 1 167 172 12649365
16. Selective inhibition of 11beta-hydroysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. P Alberts L Engblom N Edling M Forsgren G Klingstrom C Larsson Y Ronquist-Nii B Ohman L Abrahmsen, Diabetologia 2002 45 1528 1532 12436336
17. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. M Wamil JR Seckl, Drug Discov Today 2007 12 13/14 504 520 17631244
18. Lipoprotein lipase activity in the skeletal muscle is related to insulin sensitivity. T Pollare B Vessby H Lithell, Arterioscler Thromb Vasc Biol 1991 11 1192 1203
19. Potential Role of TNF-alpha and Lipoprotein Lipase as Candidate Genes for Obesity. P Kern, J Nutr 1997 127 1917S 1922S 9278582
20. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. O Hanyu T Miida K Obayashi T Ikarashi S Soda S Kaneko S Hirayama K Suzuki Y Nakamura K Yamatani Y Aizawa, Atherosclerosis 2004 174 385 390 15136071
21. Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level. S Enerback JM Gimble, Biochim Biophys Acta 1993 1169 107 125 8343535
22. A Synthetic Triterpenoid, 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO), Is A Ligand for the Peroxisome Proliferator-Activated Receptor Gamma. Y Wang WW Porter N Suh T Honda GW Gribble LM Leesnitzer KD Plunket DJ Mangelsdorf SG Blanchard TM Willson MB Sporn, Mol Endocrinol 2000 14 10 1550 1556 11043571
23. Dehydrotrametenolic Acid Induces Preadipocyte Differentiation and Sensitizes Animal Models of Noninsulin-Dependent Diabetes Mellitus to Insulin. M Sato T Tai Y Nunoura Y Yajima S Kawashima K Tanaka, Biol Pharm Bull 2002 15 1 81 86
24. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. A Hermanowski-Vosatka JM Balkovec K Cheng HY Chen M Hernandez GC Koo CB Le Grand Z Li JM Metzger SS Mundt H Noonan CN Nunes SH Olson B Pikounis N Ren N Robertson JM Schaeffer K Shah MS Springer AM Strack M Strowski K Wu T Wu J Xiao BB Zhang SD Wright R Thieringer, J Exp Med 2005 202 4 517 527 16103409
25. Peroxisome Proliferator-activated Receptor-gamma Ligands Inhibit Adipocyte 11beta-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity. J Berger M Tanen A Elbrecht A Hermanowski-Vosatka DE Moller SD Wright R Thieringer, J Biol Chem 2001 276 16 12629 12635 11278270
26. Obesity-Related Derangements in Metabolic Regulation. DM Muoio CB Newgard, Annu Rev Biochem 2006 75 367 401 16756496
27. Prediction of Glycyrrhizin Disposition in Rat and Man by a Physiologically Based Pharmacokinetic Model. S Ishida Y Sakiya T Ichikawa Z Taira S Awazu, Chem Pharm Bull 1990 38 1 212 218 2337943 (Pubitemid 20138395)
28. Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity. M McCarty, Med Hypotheses 2001 57 2 192 200 11461172
29. 11beta-HSD1 inhibition improves triglyceridaemia through reduced liver VLDL secretion and partitions lipids towards oxidative tissues. M Berthiaume M Laplante WT Festuccia K Cianflone LP Turcotte DR Joanisse G Olivecrona R Thieringer Y Deshaies, Am J Physiol Endocrinol Metab 2007 293 E1045 E1052 17666487
30. Mechanisms of Action of Fibrates on Lipid and Lipoprotein Metabolism. B Staels J Dallongeville J Auwerx K Schoojans E Leitersdorf JC Fruchart, Circulation 1998 98 2088 2093 9808609
31. Energy release from fat. WH Elliot DC Elliot, Biochemistry and Molecular Biology Oxford: Oxford University Press 3 2005 226 232
32. Protein-Mediated Fatty Acid Uptake: Novel Insights from In Vivo Models. H Doege A Stahl, Physiology 2006 21 259 268 16868315
33. Mobilisation of triacylglycerol stores. GF Gibbons K Islam RJ Pease, Biochim Biophys Acta 2000 1483 37 57 10601694
34. Increasing apo A-I production as a target for CHD risk reduction. SPJ Dullens J Plat RP Mensink, Nutr Metab Cardiovas 2007 17 616 628
35. Lipid transport. MI Gurr JL Harwood KN Frayn, Lipid Biochemistry: An Introduction Oxford: Blackwell Science 5 2002 170 212
36. Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus. KCB Tan SWM Shiu BYM Chu, Atherosclerosis 1999 145 273 278 10488953
37. Overexpression of Lipoprotein Lipase in Transgenic Watanabe Heritable Hyperlipidemic Rabbits Improves Hyperlipidemia and Obesity. T Koike J Liang X Wang T Ichikawa M Shiomi G Liu H Sun S Kitajima M Morimoto T Watanabe N Yamada J Fan, J Biol Chem 2004 279 9 7521 7529 14660566
38. Genomics of the Human Carnitine Acyltransferase Genes. FR van der Leiji NCA Huijkman C Boomsma JRG Kuipers B Bartelds, Mol Genet Metab 2000 71 139 153 11001805
39. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPAR-alpha. CD Kane OL Francone KA Stevens, Gene 2006 380 84 94 16828988
40. Role of Peroxisome Proliferator-Activated Receptor-gamma in the Glucose-sensing Apparatus of Liver and Beta-cells. H Kim Y Ahn, Diabetes 2004 53 1 S60 S65 14749267
41. Effects of glycyrrhetinic acid derivatives on hepatic and renal 11beta-hydroxysteroid dehydrogenase activities in rats. Y Shimoyama K Hirabayashi H Matsumoto T Sato S Shibata H Inoue, J Pharm Pharmacol 2003 55 811 817 12841942
42. Influence of aldosterone vs endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. T Quaschning F Ruschitzka B Niggli CMB Lunt S Shaw M Christ M Wehling TF Luscher, Nephrol Dial Transplant 2001 16 2146 2151 11682659 (Pubitemid 33062135)
43. Estimation of the concentration of LDL-cholesterol in plasma without use of the preparative ultracentrifuge. WT Friedewald RI Levy DS Fredrickson, Clin Chem 1972 18 499 502 4337382
44. Optimisation of Oil Red O staining permits combination with immunofluorescence and automated quantification of lipids. R Koopman G Schaart MKC Hesselink, Histochem Cell Biol 2001 116 63 68 11479724